A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (keratitis, dendritic)...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding herpes simplex virus keratitis can be frustrating. This condition affects a relatively small population, which can restrict systematic clinical studies and comprehensive data collection. Additionally, the clinical features have not been systematically documented, leading to gaps in understanding the full spectrum of the disease.
To navigate your care effectively, consider seeking a specialist in ophthalmology, particularly one with expertise in viral infections of the eye. While there are no patient organizations specifically identified for herpes simplex virus keratitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in clinical trials may offer access to cutting-edge treatments and contribute to the understanding of this condition.
There are currently three active clinical trials investigating herpes simplex virus keratitis. Notable orphan drugs designated for this condition include acyclovir and an HSV-1-erasing lentivirus-like particle that delivers a gRNA-expressing cassette and SpCas9 mRNA. For more details on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=herpes%20simplex%20virus%20keratitis.
Actionable guidance for navigating care for herpes simplex virus keratitis
To navigate your care effectively, consider seeking a specialist in ophthalmology, particularly one with expertise in viral infections of the eye. While there are no patient organizations specifically identified for herpes simplex virus keratitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in clinical trials may offer access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding herpes simplex virus keratitis can be frustrating. This condition affects a relatively small population, which can restrict systematic clinical studies and comprehensive data collection. Additionally, the clinical features have not been systematically documented, leading to gaps in understanding the full spectrum of the disease.
To navigate your care effectively, consider seeking a specialist in ophthalmology, particularly one with expertise in viral infections of the eye. While there are no patient organizations specifically identified for herpes simplex virus keratitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in clinical trials may offer access to cutting-edge treatments and contribute to the understanding of this condition.
There are currently three active clinical trials investigating herpes simplex virus keratitis. Notable orphan drugs designated for this condition include acyclovir and an HSV-1-erasing lentivirus-like particle that delivers a gRNA-expressing cassette and SpCas9 mRNA. For more details on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=herpes%20simplex%20virus%20keratitis.
Actionable guidance for navigating care for herpes simplex virus keratitis
To navigate your care effectively, consider seeking a specialist in ophthalmology, particularly one with expertise in viral infections of the eye. While there are no patient organizations specifically identified for herpes simplex virus keratitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in clinical trials may offer access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding herpes simplex virus keratitis can be frustrating. This condition affects a relatively small population, which can restrict systematic clinical studies and comprehensive data collection. Additionally, the clinical features have not been systematically documented, leading to gaps in understanding the full spectrum of the disease.
To navigate your care effectively, consider seeking a specialist in ophthalmology, particularly one with expertise in viral infections of the eye. While there are no patient organizations specifically identified for herpes simplex virus keratitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in clinical trials may offer access to cutting-edge treatments and contribute to the understanding of this condition.
There are currently three active clinical trials investigating herpes simplex virus keratitis. Notable orphan drugs designated for this condition include acyclovir and an HSV-1-erasing lentivirus-like particle that delivers a gRNA-expressing cassette and SpCas9 mRNA. For more details on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=herpes%20simplex%20virus%20keratitis.
Actionable guidance for navigating care for herpes simplex virus keratitis
To navigate your care effectively, consider seeking a specialist in ophthalmology, particularly one with expertise in viral infections of the eye. While there are no patient organizations specifically identified for herpes simplex virus keratitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in clinical trials may offer access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.